Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Succeeds In Changing EMA Ruling On Avastin

This article was originally published in The Pink Sheet Daily

Executive Summary

The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.

You may also be interested in...



Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results

The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.

Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results

The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.

Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim

Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.

Related Content

Topics

UsernamePublicRestriction

Register

PS072117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel